Alnylam Pharmaceuticals, Inc.
NASDAQAlnylam Pharmaceuticals heads into its Q1 2026 earnings today with options traders sending a strikingly bullish signal — the most bullish in at least a year. The put/call ratio dropped to 0.39 on May 19, three standard deviations below its 20-day mean of 0.47. That is the lowest reading in the past 52 weeks, against a full-year low of 0.36. The data points to an unusually sharp…
Snapshot as of 20 May 2026
Alnylam Pharmaceuticals heads into its Q1 2026 earnings today with options traders sending a strikingly bullish signal — the most bullish in at least a year. The put/call ratio dropped to 0.39 on May 19, three standard…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ALNY — free to start on ORTEX.
Sign up for free →Open ALNY on ORTEX